MicroRNA Therapies Market - Forecast(2024 - 2030)

Report Code: HCR 1564 Report Format: PDF + Excel

MicroRNA Therapies Market Overview:

MicroRNA Therapies Market size is estimated to reach $7 billion by 2030, growing at a CAGR of 12.5% during the forecast period 2024-2030. The rapid development and regulatory approval of emerging miRNA-based therapeutics led to the growth of the  MicroRNA Therapies Market. This trend is expected to boost the growth of the MicroRNA Therapies Market during the forecast period.

MicroRNA (miRNA) therapies refer to a class of therapeutic interventions that involve the modulation of microRNA levels in the body to treat or manage various diseases. MicroRNAs are small RNA molecules that play a crucial role in regulating gene expression. The road to approval for miRNA therapies appears to be faster than that of conventional drugs, potentially leading to quicker advancements in treatment options. This trend signifies the growing recognition of miRNA therapies as a viable and efficient approach in molecular medicine. These factors positively influence the microRNA Therapies industry outlook during the forecast period.

Market Snapshot: 


MicroRNA Therapies Market - Report Coverage:

The “MicroRNA Therapies Market Report - Forecast (2024-2030)” by IndustryARC, covers an in-depth analysis of the following segments in the MicroRNA Therapies Market.



By Product Type

  • miRNA Mimics

  •  Antagomirs or Inhibitors

By Technology

  • Microarrays

  • Next Generation Sequencing (NGS)

  • Quantitative Real Time PCR (qRT-PCR)

  • Northern Blotting

  • In Situ Hybridization (ISH)

By Application

  • Cancer

  • Infectious Diseases

  • Immunological Disorder

  •  Cardiovascular Diseases

  • Neurological Diseases

  • Other

By End-User

  • Biotechnology &Pharmaceutical Companies

  • Academic & Government Research Institutes

  • Others

By Geography

  • North America (U.S., Canada and Mexico)

  • Europe (Germany, France, UK, Italy, Spain, Russia and Rest of Europe),

  • Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand and Rest of Asia-Pacific),

  • South America (Brazil, Argentina, Chile, Colombia and Rest of South America)

  • Rest of the World (Middle East and Africa).

COVID-19 / Ukraine Crisis - Impact Analysis:  

• The Covid-19 epidemic has had a complex and multifaceted impact on the MicroRNA Therapies market's growth trajectory. On the one hand, the pandemic has highlighted the critical need for novel therapeutic techniques, particularly those based on microRNA, to address the virus's problems. This has the potential to increase attention and funding in the development of MicroRNA Therapies as a promising antiviral therapy route. The pandemic, on the other hand, has changed the overall healthcare landscape, diverting resources and attention to immediate and pressing public health concern. Clinical trials, research, and development activities linked to MicroRNA Therapies may have been delayed or reallocated, slowing progress in this sector. Furthermore, the economic consequences of the pandemic may have influenced financing availability and investment decisions, hence influencing the whole funding ecosystem for biotechnological and pharmaceutical endeavors, including MicroRNA Therapies. Despite these obstacles, the pandemic's enhanced awareness of the necessity of targeted and precision medicine may position MicroRNA Therapies for further growth and investigation in the post-Covid future.

● The ongoing Russia-Ukraine conflict has cast a shadow on various industries, including the field of microRNA therapies. The cumulative impact of the Russia-Ukraine conflict, on the other hand, is expected to have major long-term implications on the worldwide microRNA market. Unfortunately, the available search results do not provide particular facts on how the war directly affected the expansion of MicroRNA Therapies. It's important to highlight that geopolitical conflicts can disrupt supply chains, disrupt research collaborations, and undermine investor confidence, thus hindering the development and commercialization of innovative medical innovations like microRNA therapies. However, further in-depth study and industry reports focused on this specific component may be required for exact insights into the war's immediate impact.

Key Takeaways:

● North-America Region Contributes to the Highest Market Share

Geographically, in the global microRNA Therapies market share, North-America has highest share 35% in 2023 due to its dynamic and creative healthcare ecosystem. The region has a strong network of R&D centers, which include prestigious institutions, universities, and cutting-edge biotechnology firms. These entities actively contribute to the investigation of innovative therapeutic routes, such as the creation of microRNA-based therapies.

The United States, in particular, stands out for its strong biotechnology and pharmaceutical industries, which are distinguished by substantial investments in research and development. This dedication extends to the study of microRNAs, their functions in numerous diseases, and the therapeutic promise they hold. The region's concentration on creating an environment conducive to scientific inquiry and technical developments accelerates progress in MicroRNA Therapies, establishing North America as a significant role in the worldwide expansion of this burgeoning medical sector.

● Cancer Segment to Register the Fastest Growth

In the MicroRNA Therapies Market analysis, the Cancer segment is estimated to grow with the fastest CAGR of 13.8% during the forecast period 2024-2030. MicroRNA treatments, which offer a targeted and personalized approach to cancer treatment, have showed tremendous promise in the field of oncology. Because of the high prevalence of cancer in the region, there is a greater emphasis on creating novel and effective therapy options. North American academic institutes and biotechnology firms have been at the forefront of utilizing microRNAs' potential to alter gene expression and regulate key pathways involved in cancer progression. 

The delicate roles that microRNAs play in diverse forms of cancer, impacting cellular processes such as proliferation, apoptosis, and metastasis, are becoming more understood. This understanding has motivated considerable research efforts to discover individual microRNAs linked to various cancer types and create medicines that can modify these molecules to combat the disease.

● The Academic and Government Research Institutes Dominates the Growth of the Market

According to the MicroRNA Therapies Market forecast, the Academic and Government Research Institutes sector is estimated to register the fastest growth during the forecast period with a CAGR of 13.9% during forecast period 2024-2030 due to their contributions to scientific understanding, innovation, and regulatory advancements. These institutes serve as cutting-edge research hubs, laying the groundwork for the development of MicroRNA-based therapeutics. In these situations, researchers frequently investigate the complex mechanisms of MicroRNA regulation, discover new therapeutic targets, and undertake preclinical studies to validate the efficacy and safety of MicroRNA therapeutics. Their discoveries not only improve our understanding of the underlying biological mechanisms but also provide useful information for optimizing therapeutic therapies.

In addition, academia and government organizations routinely engage with commercial partners and pharmaceutical companies to put research discoveries into practical medicinal applications. This collaborative strategy hastens the development and commercialization of MicroRNA therapeutics, enabling a dynamic ecosystem in which scientific discoveries move effortlessly from the laboratory to clinical settings. In addition to doing research, these institutes play an important role in developing regulatory frameworks and recommendations. They collaborate with regulatory bodies to develop standardized processes for the evaluation and approval of MicroRNA therapies, ensuring that these innovative treatments meet severe safety and efficacy criteria.

● Growing Advancements in Molecular Biology and Genomics

Significant advances in molecular biology and genomics are propelling the expansion of the MicroRNA Therapies market, leading to a better understanding of the complex regulatory roles that microRNAs play in gene expression. Researchers are identifying distinct microRNA profiles linked to a variety of disorders, providing significant insight into possible treatment targets. Pharmaceutical companies are more positioned to produce highly targeted and effective MicroRNA therapeutics as the information base grows. This enhanced understanding of disease molecular pathways improves the precision and therapeutic potential of MicroRNA-based therapies, propelling the market ahead.

Furthermore, advances in high-throughput sequencing methods have sped up the detection of dysregulated microRNAs in diseased circumstances. This richness of genomic data not only benefits in target discovery but also in the creation of personalized MicroRNA therapies customized to unique patient profiles, which contributes to market growth.

● Technological Advancements in RNA-based Therapeutics

Technological improvements in RNA-based treatment platforms are a key driver of the MicroRNA Therapies market. Researchers and biopharmaceutical businesses are making significant progress in overcoming past barriers to the delivery and stability of RNA molecules, especially microRNAs. Bioavailability and targeted delivery of MicroRNA therapies to specific tissues or cells are improved by advancements in delivery technologies such as lipid nanoparticles and viral vectors. Nucleotide modification strategies help to improve MicroRNA stability and efficacy even more. These technological advances not only improve the pharmacokinetics of MicroRNA treatments, but also their safety characteristics. As the science of RNA treatments advances, the attractiveness of MicroRNA-based interventions grows, propelling the market's rise.

● Delivery Challenges and Tissue Specificity restrain the growth of the MicroRNA Therapies Market

The effective delivery of microRNAs to target tissues is one of the key problems confronting the MicroRNA Therapies industry. MicroRNAs are intrinsically fragile and can be rapidly destroyed in the bloodstream, making sufficient quantities at the target areas of action difficult to achieve. Furthermore, ensuring that microRNAs are delivered to the appropriate tissues while avoiding off-target effects remains a substantial challenge. The study of reliable and targeted delivery mechanisms, such as nanoparticles or viral vectors, is underway. Overcoming these delivery issues is critical for optimizing MicroRNA therapeutic efficacy and realizing their full promise in clinical settings.
                                                                   MicroRNA Therapies Market Share (%) By Region, 2023

Key Market Players: 

Product/Service launches, approvals, patents and events, acquisitions, partnerships and collaborations are key strategies adopted by players in the MicroRNA Therapies Market. The top 10 companies in this industry are listed below:

  1. Thermo Fisher Scientific, Inc. (miRNA Profiling with Real-Time PCR)
  2. Regulus Therapeutics (RGLS8429)
  3. Horizon Discovery Ltd. (miRIDIAN microRNA Mimic, shMIMIC Lentiviral microRNA)
  4. QIAGEN (miRCURY LNA miRNA PCR Assays, miScript miRNA Mimics)
  5. GeneCopoeia (microRNA Solutions)
  6. New England Biolabs (Universal miRNA Cloning Linker)
  7. Quantabio (qScript® microRNA cDNA Synthesis Kit)
  8. BioGenex (miRNA Probes, Prostate Cancer (PC) and Benign Prostatic Hyperplasia (BPH) Differentiation by New miRNA Biomarker Panel)
  9. SeqMatic LLC (miRNA & Small RNA Sequencing Services)
  10. Sistemic Scotland Limited (SistemRNA™ : Drug Repositioning & Re-purposing in vitro)

Scope of Report: 

Report Metric


Base Year Considered


Forecast Period




Market Size in 2030

$7 billion

Segments Covered

Product Type, Technology, Application, End-User and Region

Geographies Covered

North America (U.S., Canada and Mexico), Europe (Germany, France, UK, Italy, Spain, Russia and Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia, New Zealand and Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia and Rest of South America), Rest of the World (Middle East and Africa).

Key Market Players

  1. Thermo Fisher Scientific, Inc.

  2. Regulus Therapeutics

  3. Horizon Discovery Ltd.


  5. GeneCopoeia

  6. New England Biolabs

  7. Quantabio

  8. BioGenex

  9. SeqMatic LLC

  10. Sistemic Scotland Limited

For more Lifesciences and Healthcare Market reports, please click here
1. MicroRNA Therapies Market - Overview
    1.1. Definitions and Scope
2. MicroRNA Therapies Market - Executive Summary
3. MicroRNA Therapies Market - Comparative Analysis
    3.1. Company Benchmarking - Key Companies
    3.2. Global Financial Analysis - Key Companies
    3.3. Market Share Analysis - Key Companies
    3.4. Patent Analysis
    3.5. Pricing Analysis
4. MicroRNA Therapies Market - Start-up Companies Scenario (Premium)
    4.1. Key Start-up Company Analysis by
        4.1.1. Investment
        4.1.2. Revenue
        4.1.3. Venture Capital and Funding Scenario
5. MicroRNA Therapies Market – Market Entry Scenario Premium (Premium)
    5.1. Regulatory Framework Overview
    5.2. New Business and Ease of Doing Business Index
    5.3. Case Studies of Successful Ventures
6. MicroRNA Therapies Market - Forces
    6.1. Market Drivers
    6.2. Market Constraints
    6.3. Market Challenges
    6.4. Porter's Five Force Model
        6.4.1. Bargaining Power of Suppliers
        6.4.2. Bargaining Powers of Customers
        6.4.3. Threat of New Entrants
        6.4.4. Rivalry Among Existing Players
        6.4.5. Threat of Substitutes
7. MicroRNA Therapies Market – Strategic Analysis
    7.1. Value Chain Analysis
    7.2. Opportunities Analysis
    7.3. Market Life Cycle
8. MicroRNA Therapies Market – by Product Type (Market Size – $Million/$Billion) 
    8.1. miRNA Mimics
    8.2. Antagomirs or Inhibitors
9. MicroRNA Therapies Market – by Technology (Market Size – $Million/$Billion) 
    9.1. Microarrays
    9.2. Next Generation Sequencing (NGS)
    9.3. Quantitative Real-Time PCR (qRT-PCR)
    9.4. Northern Blotting
    9.5. In Situ Hybridization (ISH)
10. MicroRNA Therapies Market – by Technology (Market Size – $Million/$Billion)
    10.1. Cancer
    10.2. Infectious Diseases
    10.3. Immunological Disorder
    10.4. Cardiovascular Diseases 
    10.5. Neurological Diseases 
    10.6. Other
11. MicroRNA Therapies Market – by End-User (Market Size – $Million/$Billion) 
    11.1. Biotechnology &Pharmaceutical Companies 
    11.2. Academic & Government Research Institutes
    11.3. Others
12. MicroRNA Therapies Market – by Geography (Market Size – $Million/$Billion) 
    12.1. North America
        12.1.1. The U.S.
        12.1.2. Canada
        12.1.3. Mexico
    12.2. Europe
        12.2.1. UK
        12.2.2. Germany
        12.2.3. France
        12.2.4. Italy
        12.2.5. Spain
        12.2.6. Russia
        12.2.7. Rest of Europe
    12.3. Asia-Pacific
        12.3.1. China
        12.3.2. India
        12.3.3. Japan
        12.3.4. South Korea
        12.3.5. Australia & New Zealand
        12.3.6. Rest of Asia-Pacific
    12.4. South America
        12.4.1. Brazil
        12.4.2. Argentina
        12.4.3. Chile
        12.4.4. Colombia
        12.4.5. Rest of South America
    12.5. Rest of the World
        12.5.1. Middle East
        12.5.2. Africa
13. MicroRNA Therapies Market – Entropy
14. MicroRNA Therapies Market – Industry/Segment Competition Landscape Premium 
    14.1. Market Share Analysis
        14.1.1. Market Share by Product Type – Key Companies
        14.1.2. Market Share by Region – Key Companies
        14.1.3. Market Share by Country – Key Companies
    14.2. Competition Matrix
    14.3. Best Practices for Companies
15. MicroRNA Therapies Market – Key Company List by Country Premium Premium 
16. MicroRNA Therapies Market - Company Analysis
    16.1. Thermo Fisher Scientific, Inc. 
    16.2. Regulus Therapeutics 
    16.3. Horizon Discovery Ltd. 
    16.4. QIAGEN 
    16.5. GeneCopoeia 
    16.6. New England Biolabs 
    16.7. Quantabio 
    16.8. BioGenex 
    16.9. SeqMatic LLC 
    16.10. Sistemic Scotland Limited

"Financials to the Private Companies would be provided on best-effort basis."Connect with our experts to get customized reports that best suit your requirements. Our reports include global-level data, niche markets and competitive landscape.

The MicroRNA Therapies Market is projected to grow at 12.5% CAGR during the forecast period 2024-2030.

Global MicroRNA Therapies Market size is estimated to be $2.5 billion in 2023 and is projected to reach $7 billion by 2030.

The leading players in the MicroRNA Therapies Market are Thermo Fisher Scientific, Inc., Regulus Therapeutics, Horizon Discovery Ltd., QIAGEN, GeneCopoeia and others.

Personalized Medicine and Biomarker Discovery, Collaboration and Partnerships and Expansion of Therapeutic Indications are some of the major MicroRNA Therapies Market trends in the industry which will create growth opportunities for the market during the forecast period.

Advancements in Molecular Biology and Genomics and Technological Advancements in RNA-based Therapeutics are the driving factors of the market.